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Muscular dystrophies (MDs) are caused by genetic muta-
tions in over 30 different genes, many of which encode 
for proteins essential for the integrity of muscle cell struc-
ture and membrane. Their deficiencies cause the muscle 
vulnerable to mechanical and biochemical damages, 
leading to membrane leakage, dystrophic pathology, 
and eventual loss of muscle cells. Recent studies report 
that MG53, a muscle-specific TRIM-family protein, plays 
an essential role in sarcolemmal membrane repair. Here, 
we show that systemic delivery and muscle-specific over-
expression of human MG53 gene by recombinant ade-
no-associated virus (AAV) vectors enhanced membrane 
repair, ameliorated pathology, and improved muscle 
and heart functions in δ-sarcoglycan (δ-SG)-deficient 
TO-2 hamsters, an animal model of MD and conges-
tive heart failure. In addition, MG53 overexpression 
increased dysferlin level and facilitated its trafficking to 
muscle membrane through participation of caveolin-3. 
MG53 also protected muscle cells by activating cell sur-
vival kinases, such as Akt, extracellular signal-regulated 
kinases (ERK1/2), and glycogen synthase kinase-3β 
(GSK-3β) and inhibiting proapoptotic protein Bax. Our 
results suggest that enhancing the muscle membrane 
repair machinery could be a novel therapeutic approach 
for MD and cardiomyopathy, as demonstrated here in 
the limb girdle MD (LGMD) 2F model.
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IntroductIon
Functional deficiencies of proteins involved in the maintenance 
of sarcolemmal membrane integrity or repair are commonly 
observed in muscular dystrophies (MDs), which are resulted from 
genetic mutations. For example, mutations of dystrophin gene in 
Duchenne and Becker MDs or sarcoglycan genes in limb girdle 
MDs (LGMDs) lead to muscle sarcolemma destabilization and 
fragility. The myofibers become highly susceptible to contraction-
induced injures, which are manifested by elevated muscle creatine 
kinase (CK) activity in the serum and muscle degeneration. No 
effective treatment is currently available for any form of MD. A 
majority of the current experimental therapeutic strategies focus 
on the restoration of the specific muscle protein encoded by the 
individual gene that is mutated.1–5 Since many MDs share simi-
lar pathological consequences from sarcolemma damage, in this 
study, we have investigated a gene therapy strategy that aims at 
repairing the leaky cell membranes rather than targeting specific 
genetic mutations. Abnormal extracellular Ca2+ influx was found 
in recent studies sufficient to induce dystrophic phenotypes, 
whereas sequestration of the influxed Ca2+ improved dystrophic 
muscle pathology and functions.6,7 We reason that enhanced mem-
brane repair should be beneficial by resealing the leaky membrane, 
preventing Ca2+ influx and maintaining cellular homeostasis.
Muscle membrane repair is a conserved, multicomponent 
process and involves Ca2+-triggered intracellular vesicles exocy-
tosis toward the injury site, followed by vesicle fusion at mem-
brane lesions.8 A Ca2+-dependent muscle-specific fusogen, 
dysferlin, is one of the first proteins identified in the membrane 
repair machinery in both skeletal and cardiac muscle. Dysferlin-
deficiency causes LGMD 2B.8–10 Gene delivery of dysferlin restored 
membrane repair in a dysferlin-deficient mouse model.5 However, 
dysferlin is not necessary for the recruitment of vesicles to the 
membrane injury sites, although it is a key player in membrane 
repair.8–11
MG53, a muscle-specific tripartite motif family protein 
(TRIM72), was recently shown to be an essential component of 
the membrane repair system necessary for vesicle trafficking to 
the injury sites.12 MG53-mediated intracellular vesicle trafficking 
acts upstream of dysferlin movement to the damaged sarcolem-
ma.13 Additional experiments demonstrated that MG53 interacts 
with dysferlin and caveolin-3, another muscle-specific protein, to 
facilitate skeletal muscle membrane repair upon influx of extra-
cellular Ca2+ at the injury sites.11 Given the pivotal role of MG53, 
increasing its expression to enhance muscle membrane repair 
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prior to the downstream events of myofiber necrosis and apopto-
sis represents a novel approach for in vivo therapeutic studies in 
animal models of MDs. However, overexpression of MG53 in vivo 
has not been achieved before.
In the present study, we used the δ-sarcoglycan (δ-SG)-
deficient MD and cardiomyopathy TO-2 hamster model to 
investigate the therapeutic efficacy of human MG53 (hMG53) 
gene transfer and overexpression by systemic adeno-associated 
virus 8 (AAV8) delivery. We previously showed that systemic 
delivery of human δ-SG gene by AAV8 achieved global and 
long-term therapeutic effects in TO-2 hamsters.3,14,15 Here, we 
showed that MG53 gene transfer in both neonates and adults 
achieved efficient sarcolemma repair in vivo and in vitro, result-
ing in systemic amelioration of myopathies and functional res-
cue of skeletal muscle and heart. Therapeutic efficacy and safety 
were further improved by a combination of a muscle-specific 
promoter and a liver microRNA (miRNA) target sequence to 
assure heart- and muscle-specific transgene expression. MG53 
gene therapy also increased dysferlin expression and facilitated 
its trafficking to muscle membrane through participation of 
caveolin-3. Furthermore, phosphorylation of several survival 
kinases, such as Akt, ERK1/2, and glycogen synthase kinase 
(GSK), were elevated, while the proapoptotic Bcl-2 molecules, 
such as Bax, were reduced in gene therapy treated TO-2 skeletal 
muscle and heart.
results
systemic and long-term gene transfer of MG53 in 
dystrophic to-2 hamsters by AAV8 vectors
Since MG53 is a muscle-specific protein, we generated AAV8 vec-
tors carrying muscle-specific CK promoter to control the gene 
expression of a myc-tagged human MG53. Efficient gene transfer 
in the heart and skeletal muscles was achieved by vector injection 
either intraperitoneally in 10-day-old TO-2 neonates (1 × 1013 vec-
tor genomes/kg bodyweight, vg/kg) or intravenously in 2-month-
old TO-2 adults (2 × 1013 vg/kg). When examined at 2 months 
postinjection by myc-tag immunofluorescent staining, expression 
of myc-MG53 was observed in the treated muscles, but no staining 
appeared in the muscle of control hamsters (Figure 1a,b). Muscle-
specific myc-MG53 expression was further confirmed by western 
blot (Figure 1c). These results indicated that systemic delivery of 
MG53 was robust and stable in the heart and skeletal muscle of 
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Figure 1 Muscle membrane integrity improvement in to-2 skeletal and cardiac muscles via systemic delivery of AAV8-MG53.(a) Immuno-
fluorescent (IF) staining of myc-tagged-MG53 expression in muscles of neonatally treated TO-2 hamsters at vector dose of 1 × 1013 vg/kg. Samples 
were collected 2 months later. Age-matched untreated TO-2 served as controls (n = 5 per group; bar = 100 µm). (b) The same as in (a) except that 
a vector dose of 2 × 1013 vg/kg was delivered in 2-month-old TO-2 hamsters. Samples were collected at 2 months after injection (n = 5 per group; 
bar = 100 µm). (c) Western analysis of myc-tagged-MG53 in muscle and nonmuscle tissues in both neonate-treated and adult-treated TO-2 ham-
sters. Samples collected were same as described in (a) and (b). Muscles included tibialis anterior (TA), gastrocnemius (GAS), triceps (TRI), quadriceps 
(QD), heart, diaphragm (DIA), abdominal muscle (ABD), masseter (MA), and intercostal muscle (ITM). Nonmuscle tissues included liver, pancreas 
(PAN), kidney, and lung. (d) Improvement in muscle membrane integrity as revealed by exclusion of Evan blue dye (red fluorescence) in muscle and 
heart at 2 month after neonatal injection (1 × 1013 vg/kg). (e) Reduction of serum CK levels after delivery of AAV8-MG53 in newborn hamsters. Low 
dose: 1 × 1013 vg/kg; high dose: 1 × 1014 vg/kg. *P < 0.05 versus the untreated TO-2. (f) Reduction of serum CK level after delivery of AAV8-MG53 
(2 × 1013 vg/kg) in adult hamsters. *P < 0.05 versus the untreated TO-2. (g) Time-course of FM1-43 accumulation at injury sites of the isolated 
single myofibers following UV-laser induced membrane damage in the presence of 2 mmol/l Ca2+ in solution. Values represent mean ± SD. P < 0.01 
when AAV-MG53 treated (1 × 1013 vg/kg) versus the untreated TO-2 myofibers. (h) The same as in (g) except the absence of extracellular Ca2+ (plus 
0.5 mmol/l EGTA). Values represent mean ± SD. AAV, adeno-associated virus.
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restoration of to-2 muscle cell integrity by  
MG53-mediated membrane repair
δ-SG deficiency in TO-2 hamsters leads to chronic damage to 
the myofiber and leaky sarcolemma that is a major cause of 
pathology in these dystrophic muscles. We examined whether 
MG53 gene transfer could improve muscle membrane repair 
and integrity at both cellular and bodywide levels. In vivo 
examination of membrane integrity by intravenous injection of 
Evans Blue, a sarcolemma-impermeable dye, was performed 2 
months after AAV treatment. Muscle thin sections showed that 
MG53 overexpression largely prevented the dye from enter-
ing muscle cells of the tibialis anterior (TA), gastrocnemius 
(GAS), and heart in TO-2 hamsters neonatally treated with 
AAV8-MG53 (1 × 1013 vg/kg). As expected, pronounced muscle 
membrane leakage in the untreated TO-2 hamsters was found, 
whereas the wild-type (WT) F1B control hamsters showed no 
leakage (Figure 1d). Additional evidence of sarcolemma integ-
rity improvement was the diminution of the elevated serum CK 
levels at 1, 2.5, and 4 months after neonatal treatment with both 
low and high vector doses (1 × 1013 and 1 × 1014 vg/kg) com-
pared to the untreated age-matched TO-2 hamsters (Figure 1e). 
In addition, vector-treatment in the 2-month-old adult TO-2 
hamsters, which already displayed dystrophic pathology, also 
significantly decreased CK activities when examined at 1 and 
2 months after vector injection (2 × 1013 vg/kg) (Figure 1f). 
Together, both histological and biochemical results suggest 
that AAV8-mediated MG53 systemic gene transfer increased 
membrane resealing in dystrophic muscle and heart, partially 
restored membrane integrity, and ameliorated muscle pathol-
ogy. Interestingly, in the neonatally treated TO-2 hamsters, 
more beneficial effects were observed in the groups with lower 
vector dose (1 × 1013 vg/kg), suggesting that an optimal vector 
dose threshold has been reached.
To directly evaluate the effect of MG53 gene transfer on mus-
cle membrane repair, we performed a single-myofiber membrane 
repair assay by measuring the entry of FM1-43 fluorescent dye 
following UV-laser induced membrane damage.8 Single myofi-
bers of flexor digitorum brevis muscle were isolated respectively 
from age-matched WT F1B, untreated TO-2 and TO-2 ham-
sters that were treated 3 months earlier at the neonatal age (1 × 
1013 vg/kg). In the presence of 2 mmol/l extracellular Ca2+, the 
WT F1B myofibers effectively and quickly resealed sarcolem-
mal membranes (Figure 1g, Supplementary Figure S1, top 
panel and Supplementary Video S1) but remarkable FM1-43 
dye entry into untreated TO-2 myofibers was observed due to 
compromised sarcolemmal membrane integrity (Figure 1g, 
Supplementary Figure S1, middle panel and Supplementary 
Video S2). In contrast, myofibers from AAV-MG53-treated TO-2 
effectively and quickly resealed the membrane and excluded the 
entry of FM1-43 dye following UV-laser damage to an extent 
indistinguishable from the WT F1B myofibers (Figure 1g, 
Supplementary Figure S1, bottom panel and Supplementary 
Video S3). Since MG53-mediated membrane repair is triggered 
by influx of Ca2+,12 identical FM1-43 dye entry experiments 
were repeated but in the absence of extracellular Ca2+. Marked 
FM1-43 dye entry after UV-induced wounding was seen in the 
myofibers of all three groups of hamsters regardless (Figure 1h). 
The above results demonstrated that overexpression of MG53 is 
responsible for the rescue of membrane repair in the δ-SG defi-
cient TO-2 hamsters.
Amelioration of to-2 muscle pathology by systemic 
MG53 gene delivery
We further examined whether improved membrane repair and 
subsequent restoration of sarcolemma integrity in AAV-treated 
TO-2 hamsters led to systemic amelioration of muscle histo-
pathology. Hematoxylin and eosin staining of the TA and GAS 
muscle cross-sections from WT F1B hamsters showed normal 
histology, while the untreated TO-2 hamster muscles displayed 
fibrosis, focal necrosis, and extensive central nucleation. The 
AAV-MG53-treated TA and GAS muscle collected 2 months 
after neonatal treatment (1 × 1013 vg/kg) displayed more uniform 
myofiber sizes, less mononuclear cell infiltration, and a signifi-
cant decrease in the percentage of centrally localized nuclei in TA 
(22.0 ± 3.0%) and GAS (37.0 ± 5.0%) when compared to those of 
age-matched untreated hamsters (75.0 ± 6.0% and 80.0 ± 9.0%, 
respectively) (Figure 2a,b). Furthermore, Masson’s trichrome 
staining revealed a significant reduction of fibrosis in the neo-
natally treated TO-2 skeletal muscle (TA) (Figure 2c). Tissue 
hydroxyproline content, a more quantitative index of fibrosis, 
was also significantly decreased in the AAV-MG53-treated mus-
cle at the ages 4.5 and 7.5 months (1.0 ± 0.2 and 1.7 ± 0.3 μg/mg 
dry tissue) compared to the untreated groups (2.2 ± 0.4 and 3.5 ± 
0.6 µg/mg dry tissue, respectively) (Supplementary Figure S2a). 
These data demonstrated that MG53 indeed rendered significant 
therapeutic efficacy in TO-2 muscles at the histopathological 
level.
Improvement of to-2 cardiac histology and function 
by systemic MG53 gene transfer
δ-SG-deficient TO-2 hamsters also manifest severe cardiac dys-
function and dilated congestive heart failure. Given that robust 
gene transfer of MG53 was observed in the heart (Figure 1a–c) 
that resulted in substantial reduction of cardiac sarcolemmal 
leakage (Figure 1d) and fibrosis (Figure 2d and Supplementary 
Figure S2b), we next investigated whether MG53 gene transfer 
could improve heart function in TO-2 hamsters. The noninva-
sive echocardiography was performed at 4.5 and 7.5 months of 
age in both neonatal (1 × 1013 vg/kg) and 2-month-old adult (2 
× 1013 vg/kg) treated hamsters. Compared to the age-matched 
untreated TO-2 hamsters, both treatment groups showed a signif-
icant increase in left ventricular percentage fractional shortening, 
an index of systolic function (Figure 2e). Significant reduction in 
left ventricular end-systolic and end-diastolic internal diameters 
(LVID;s and LVID;d) were also observed at the age of 7.5 months, 
at which time overt cardiac dilation occurred in TO-2 hamsters 
(Figure 2f). These results indicated MG53-mediated membrane 
repair offered partial but very significant therapeutic efficacies.
Inhibition of ectopic MG53 expression in liver by 
mirnA-mediated transgene silencing diminished 
toxicity and enhanced efficacy
Our initial pilot experiments using the nonspecific cytomega-
lovirus promoter to drive MG53 expression resulted in severe 
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growth retardation of the TO-2 neonates, suggesting potential 
toxicity due to overexpression in nonmuscle tissues, especially 
the liver. Switching to the muscle-specific CK promoter dra-
matically reduced this toxicity.16 However, since AAV8 has a 
strong hepatic tropism and delivers high copy numbers of vec-
tors to the liver,3,15,17,18 leaky expression could still occur even 
with the CK promoter.19 Indeed a slight growth delay between 
3 and 6 weeks postinjection in the neonatal-treated TO-2 ham-
sters was found (Figure 3a). Western blot analysis of muscle 
and liver samples collected 2 weeks after injection confirmed 
leaky MG53 expression in the liver (Figure 3b), which resulted 
in elevation of serum alanine transaminase levels 1 month after 
injection (Supplementary Figure S3a). However, liver expres-
sion decreased progressively post neonatal injection due to 
dilution of vector DNA after liver growth (Figure 3c). Since 
AAV8 also transduces the pancreas,18 serum amylase activ-
ity was examined but no difference was found between treat-
ment and TO-2 control group (Supplementary Figure S3b).
The lack of detectable MG53 gene expression by western blot 
(Figures 1c and 3b) confirmed the inactivity of the CK pro-
moter in the pancreas.
To further minimize MG53 expression in the liver, we used 
a miRNA-mediated transgene silencing strategy by adding the 
liver-specific miRNA-122 targeting sequence (miR-122T) to the 
3′ untranslated region of MG53 cDNA, an approach we previously 
found effective in reducing reporter gene expression in liver.20 
Injection of the TO-2 neonates with AAV-CK-MG53-miR-122T 
(1 × 1013 vg/kg) did not cause appreciable delay in body weight gain 
(Figure 3a). MG53 became undetectable in the liver by sensitive 
western blot analysis (Figure 3b,c). Serum alanine transaminase 
activity remained the same as seen in the untreated control TO-2 
hamsters (Supplementary Figure S3a). Liver-silenced vector also 
allowed for better functional recovery of whole-body strength and 
endurance as evaluated by treadmill running capacity tested at 4 
months of age. While the running distances of AAV-CK-MG53-
treated TO-2 hamsters were greater than those of the age-matched 
untreated TO-2 in both neonatal and adult treatment groups 
(Figure 3d), additional improvement was achieved in the AAV-
CK-MG53-miR-122T-treated TO-2 hamsters (Figure 3d). These 
results demonstrated that the microRNA transgene silencing 
strategy effectively diminished ectopic MG53 overexpression and 































































































































































Figure 2 Amelioration of muscle and heart degeneration and fibrosis and functional improvement in dystrophic to-2 hamsters by systemic 
MG53 gene transfer. (a) Histological improvement as assessed by hematoxylin and eosin (H&E) staining. TO-2 hamsters treated with AAV-MG53 
(1 × 1013 vg/kg) were analyzed 2 months after neonatal injection. Bar = 100 µm. (b) Decrease in central nucleation (CN) of treated muscle fibers 
described in (a). Displayed are the percentages of CN in muscle myofibers for the groups above. Values represent mean ± SD. *P < 0.01 versus 
the untreated TO-2 (n = 5 per group with 300 fibers analyzed per muscle). (c,d) Reduction of fibrosis in skeletal and cardiac muscle as evidenced 
by Masson’s trichrome staining. Samples were collected at 4.5 and 7.5 months of age after neonatal treatment (1 × 1013 vg/kg). Bar = 100 µm. 
(e) Cardiac function improvement as revealed by increase in left ventricle percent fraction shortening (% LVFS) in TO-2 hamsters treated as neonates 
(1 × 1013 vg/kg) or adults (2 × 1013 vg/kg) (Ms, months). *P < 0.05 versus the untreated TO-2 (n = 5). (f) Cardiac function improvement as revealed 
by reduction in left ventricular end-systolic and end-diastolic internal diameter (LVID;s and LVID;d)) in TO-2 treated as neonates (1 × 1013 vg/kg) 
(Ms, months). *P < 0.05 versus the untreated TO-2 (n = 5). Values represent mean ± SD. All hamsters were male. AAV, adeno-associated virus.
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elevation of dysferlin and caveolin-3 levels in  
MG53-mediated to-2 membrane repair
Abnormal localization of dysferlin was found in dystrophic myo-
cytes in LGMDs.21 Our recent studies show that MG53 could 
interact with dysferlin and caveolin-3 to regulate sarcolemmal 
membrane repair in skeletal muscle.11 We wished to examine 
whether overexpression of MG53 could increase dysferlin and 
caveolin-3. Western analysis indeed showed higher quantity of 
dysferlin and caveolin-3 proteins in the MG53-treated TO-2 
muscles, compared with both WT F1B and untreated TO-2 
muscle (Figure 4a). Immunofluorescent staining of muscle thin 
sections also showed intracellular location of MG53, dysfer-
lin, and caveolin-3. Higher levels of these three proteins were 
observed in the AAV-MG53-treated muscles (Figure 4b, right 
panels), consistent with western blot results. Interestingly, exten-
sive cytoplasmic accumulation of both dysferlin and caveolin-3 
in untreated dystrophic TO-2 muscle was observed as punctu-
ated dots of vesicles, indicative of retarded membrane repair 
(Figure 4b, panels e and f, marked by arrow head). However, 
AAV-MG53 treatment and overexpression normalized and 
redistributed dysferlin and caveolin-3 vesicles to the sarcolem-
mal membrane (Figure 4b, panels h and i), as similarly seen in 
the WT F1B muscle (Figure 4b, panels b and c). These results 
demonstrated that AAV-mediated MG53 overexpression not 
only increased the quantity of dysferlin and caveolin-3 but also 
facilitated their trafficking to and retention at the muscle mem-
brane, hence improved the membrane repair capacity of the dys-
trophic muscle.
Activation of cellular prosurvival pathways in  
MG53-treated to-2 muscle and heart
Finally, to further elucidate the mechanisms of MG53-mediated 
therapeutic effects, we investigated the status of key survival 
kinases, including Akt, extracellular signal-regulated kinases 
(ERK1/2) and GSK-3β, as well as the Bcl-2-family proapoptotic 
molecules, such as Bax, in muscle tissues.22 In vector-treated 
TO-2 hamsters, we found strong activation of muscle ERK1/2 
and a much higher ratio of p-ERK1/2/ERK1/2 compared to the 
untreated muscle (1.18 ± 0.13 versus 0.16 ± 0.02, Figure 4c). 
Furthermore, the heart of MG53-treated TO-2 also demonstrated 
significant elevation of p-ERK1/2/ERK1/2 ratio (1.33 ± 0.17 ver-
sus 0.59 ± 0.05, Figure 4d), the p-Akt/Akt ratio (0.91 ± 0.11 versus 
0.58 ± 0.08, Supplementary Figure S4a), and p-GSK-3β/GSK-3 
ratio (0.70 ± 0.16 versus 0.22 ± 0.04, Supplementary Figure S4b) 
relative to the untreated TO-2 heart, suggesting that MG53 offers 
cardiac protection in TO-2 hamsters.24
Multiple lines of evidence have indicated apoptotic cell-death 
mechanisms in neuromuscular disorders and the antiapoptosis 
therapy benefits MD.25,26 Bax is a proapoptotic Bcl-2 family protein 
and initiates apoptotic response in the mitochondrial pathway of 
apoptosis. Western blot analysis demonstrated marked decrease of 
Bax in MG53-treated versus untreated muscles (0.34 ± 0.11 versus 
1.00 ± 0.23, Figure 4e) and heart (2.83 ± 0.29 versus 4.48 ± 0.98, 
Figure 4f and Supplementary Figure S5). Thus, the therapeutic 
effects of MG53 on TO-2 skeletal muscle and heart are associated 
with activation of Akt, ERK1/2, and GSK-3β pathways and attenu-
ation of the proapoptotic Bcl-2 family molecule Bax.
Figure 3 Attenuation of MG53 overexpression-induced liver toxic-
ity by the micrornA-122 targeting sequence (mir-122t)-mediated 
transgene silencing strategy. (a) Inclusion of the liver-specific miR-
122T in AAV vector prevented the growth retardation observed in the 
AAV-CK-MG53-treated hamsters (1 × 1013 vg/kg). Values represent mean 
± SD. *P < 0.05, AAV-CK-MG53-treated versus the untreated TO-2 ham-
sters. (b) Efficient inhibition of ectopic MG53 expression in nonmuscle 
tissues by CK promoter and miR-122T. Western blot of MG53 was per-
formed for muscle and nonmuscle tissues collected 2 weeks after neo-
natal injection with different vectors as indicated (1 × 1013 vg/kg). (c) 
Efficient inhibition of ectopic MG53 expression in the AAV-CK-MG53-
treated TO-2 hamster liver by miR-122T. Western blot of MG53 was 
performed to detect leaky activities of CK promoter in the liver samples 
collected at different time points after neonatal vector injection (1 × 
1013 vg/kg). GAPDH blot was used as a loading control. (d) Improved 
treadmill running distances (meters, mean ± SD) of 4-month-old WT 
F1B, untreated TO-2, and TO-2 treated with different AAV vectors as 
indicated (1 × 1013 vg/kg for neonates and 2 × 1013 vg/kg for 2-month-
old adults). Values represent mean ± SD. *P < 0.01 versus the untreated 
TO-2; **P  < 0.05 versus TO-2 AAV-MG53 neonatal treatment (n = 5 per 
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dIscussIon
Recent reports showed that MG53 facilitates plasma membrane 
repair through intracellular vesicle translocation to the injury 
site for fusion to form a repair patch.12 Here, we investigated the 
therapeutic potential of MG53-mediated membrane repair by 
gene delivery in the δ-SG-deficient TO-2 hamsters, which display 
severe muscle cell membrane damage and manifest both muscle 
pathology and dilated congestive heart failure. Previously, we 
have successfully tested gene replacement therapy in the TO-2 
model by AAV8-δ-SG gene delivery.3,14 In the present study, we 
used the same animal model and AAV8 vector but delivered the 
MG53 gene for efficient systemic and long-term gene transfer. 
We found that enhanced membrane repair by MG53 overexpres-
sion improved membrane integrity in both skeletal and cardiac 
muscles in the TO-2 hamsters and resulted in global therapeu-
tic efficacies for MD and heart failure. To obtain muscle- specific 
transgene expression and minimize the side effects due to ecto-
pic expression, especially in the liver, we utilized a muscle-
 specific promoter and liver-specific miRNA-122 target sequence 
in the AAV-MG53 expression vector cassette. These significantly 
increased specificity of transgene expression in the muscle and 
heart and dramatically reduced ectopic expression and side 
effects in the liver. In addition, we found that MG53 overexpes-
sion elevated the levels of other important components of the 
membrane repair machinery such as dysferlin and caveolin-3. It 
also enhanced a number of key cell survival signaling pathways 
and inhibited proapoptotic molecules. Together, these favorable 
molecular mechanisms contributed to the beneficial effects of 
enhanced membrane repair by MG53 gene delivery in MD ani-
mal model.
Chronic muscle cell membrane damage is a common patho-
logical consequence of various genetic deficiencies seen in differ-
ent forms of MDs. Widely explored therapeutic strategies include 
ones that specifically restore the gene products that are deficient, 
for example, restoration of sarcoglycans for LGMDs and dystro-
phin for Duchenne and Becker MDs (DMD, BMD). However, 
these approaches are limited to the specific disease subset and 
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Figure 4 Identification of mechanisms involved in MG53-mediated therapeutic effects. (a) Western blot analysis of dysferlin and caveolin-3 in 
muscle [gastrocnemius (GAS)] tissues collected from wild-type (WT) F1B, untreated TO-2, and AAV-MG53 neonatally treated TO-2 (1 × 1013 vg/kg) 
at 4 months of age. Rabbit anit-MG53 antibody was used. GAPDH was loading control. (b) Immunofluorescent (IF) staining shows overexpression of 
MG53 in TO-2 hamster normalized and redistributed dysferlin and caveolin-3 vesicles to the sarcolemma membrane. Samples collected were same 
as described in (a). Note cytoplasmic accumulation of both dysferlin and caveolin-3 in untreated TO-2 muscle (arrow head). (c,d) Activation of cell 
survival kinase ERK and an increase in the ratio of p-ERK/ERK in muscle and heart of AAV-MG53-treated TO-2 hamsters. Representative immunoblots 
and statistical data of phosphorylated and total ERK1/2 in (c) tibialis anterior (TA) muscle and (d) heart were from 4-month-old F1B, TO-2, and TO-2 
treated with AAV (1 × 1013 vg/kg) at neonatal age. GAPDH was loading control. Values represent mean ± SD. *P < 0.01 versus the untreated TO-2 
(n = 5 hamsters per group). (e,f) Decreased proapoptotic factor Bax expression in muscle and heart of AAV-MG53-treated TO-2 hamsters. Samples 
collected were same as described in (c) and (d). Values represent mean ± SD. *P < 0.01 versus the untreated TO-2 (n = 5 hamsters per group). AAV, 
adeno-associated virus.
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in various rare MDs such as the δ-SG-deficient LGMD 2F, thera-
peutic strategies that improve and correct common pathologi-
cal pathways instead of individual genetic defects have recently 
gained ground due to their broader therapeutic potentials.6,28–31 
For example, influx of extracellular Ca2+ resulted from plasma 
membrane leakage triggers a cascade of detrimental events in 
the cells.7 Recent studies showed that enhancing intracellular 
Ca2+ handling by reducing or sequestering excessive Ca2+ in 
cytosol could protect and improve the functions of muscle and 
heart cells.6,31 MG53 renders its protective effects on the muscle 
cells by resealing the leaky membrane and preventing harmful 
extracellular Ca2+ influx, since it senses Ca2+ influx and mobi-
lizes the membrane repair machinery. Thus, upregulation of an 
endogenous protein such as MG53 for the treatment of genetic 
diseases offers a unique advantage over gene replacement ther-
apy. The latter produces a therapeutic protein that the host is 
lacking and may therefore be recognized as a neoantigen for 
immune responses. Another advantage of MG53 gene therapy 
is its broader potential for the treatment of different forms of 
MDs with leaky muscle cell membranes. However, since MG53 
is only found in the striated muscles, tissue-specific transgene 
expression is highly desirable in order to avoid adverse effects 
of MG53 overexpression in nonmuscle tissues, especially when 
high copy numbers of the AAV vectors are delivered to the liver 
after intravenous injection. To this end, we have successfully 
used two layers of regulation, a muscle promoter and a liver 
miRNA-122 target, to attain tight control of MG53 expression 
in vivo. If needed, muscle- and heart-targeting AAV vectors32,33 
can also be used as an additional option to further improve gene 
transfer specificity.
This is the first time that overexpression of MG53 has been 
tested in an in vivo model. We found that increased MG53 was 
accompanied by increased levels of dysferlin and caveolin-3, 
another two key components in the muscle membrane repair 
pathway. MG53 facilitated dysferlin’s function as a fusogen for 
intracellular vesicle trafficking to the damaged sites to form a 
membrane repair patch,8,34 while caveolin-3 functions as an 
upstream regulator for both dysferlin and MG53 by both inhib-
iting endocytosis of dysferlin from sarcolemma to cytoplasma 
and moderating excessive membrane trafficking events induced 
by MG53.13,35 The long-term therapeutic effect of MG53 in dys-
trophic muscle and heart argues for the beneficial functions of 
MG53 overexpression in striated muscle membrane repair in an 
enhanced but balanced manner in coordination with other key 
factors. Additional evidence further supports the therapeutic 
mechanisms as we detected alteration of key survival kinases 
and proapoptotic pathways following AAV-MG53 treatment, 
namely activation of ERK1/2, Akt, and GSK-3 and inhibition of 
Bcl-2 family member Bax25,26 in the muscle and heart of AAV-
MG53 treated dystrophic hamsters. These findings are consistent 
with a recent in vitro study that demonstrated the involvement of 
PI3K, Akt, GSK-3β, and ERK1/2 in the MG53-mediated cardiac 
ischemic preconditioning process.24
Finally, the limitation of surrogate gene, protein, and small 
molecule drug therapies for genetic diseases is that if the under-
lying cause of the disease is not corrected by restoration of the 
missing gene product, one can only anticipate partial therapeutic 
efficacies. MG53 gene therapy is no exception. In the δ-SG-deficient 
hamster model we achieved only partial nonetheless very signifi-
cant therapeutic benefits, which if applied to patients could trans-
late to a clinically meaningful therapy. In addition, MG53 gene 
therapy may find its way in treating ischemic heart disease and 
heart failure, where nonspecific cardiomyocyte membrane dam-
age and dysfunction of Ca2+ homeostasis are commonly found. 
MG53 should be able to help maintain cardiomyocyte membrane 
integrity and repair the leaky membrane, therefore, offer an effec-
tive treatment for cardiomyopathies that arise from compromised 
muscle membrane integrity.36
MAterIAls And Methods
AAV vector construction and production. Recombinant double-stranded 
CK promoter-driven human MG53 AAV vectors with or without the target 
sequence of the liver-specific miRNA-122 were constructed by the standard 
cloning protocols. The vector DNA was packaged into AAV8 viral particles 
by triple plasmid transfection of 293 cells37 and purified by polyethylene 
glycol precipitation followed by CsCl centrifugation.38 DNA dot blot was 
used to determine the titers of the purified viral stocks as vg/ml.
Animals and vector administration. All experiments using male TO-2 
and F1B hamsters (Bio Breeders, Fitchburg, MA) were approved by the 
Institutional Animal Care and Use Committee at the University of North 
Carolina at Chapel Hill and were in accordance with National Institutes 
of Health Guidelines. For vector administration, neonatal TO-2 ham-
sters (10–12 days old, 10 g) were intraperitoneally injected with AAV8-
CK-MG53 (low dose, 1 × 1013 vg/kg; high dose, 1 × 1014 vg/kg) in 0.2 ml of 
solution, whereas adult TO-2 hamsters (2 months old, 100 g) were intrave-
nously injected with the same vector (2 × 1013 vg/kg) in 0.3 ml of solution 
via sublingual vein.
Histology, immunochemistry, and western blot analysis. Muscle and 
other tissues were collected at the indicated time points after vector injec-
tion. For immunofluorescent staining, hematoxylin and eosin staining, and 
Masson’s trichrome staining, tissue samples were cryosectioned to a thick-
ness of 7 μm and processed according to previous publications.1 Tissue 
hydroxyproline content was measured according to the method described1 
and was normalized by dry tissue weight. For western blot, 10–30 μg of 
protein extract from homogenized hamster muscle was run on an 8–12% 
sodium dodecyl sulfate-polyacrylamide gel. The anti-hMG53 antibody 
was provided by Dr J.M. lab. Anti-Myc tag antibody (ab9106) and anti-
GAPDH antibody (ab9485) were from Abcam (Cambridge, MA). Anti-
dysferlin antibody (VP-D503) was from Vector Laboratories (Burlingame, 
CA). Anti-caveolin-3 antibody (sc-7665) was from Santa Cruz Biotech 
(Santa Cruz, CA). Anti-Akt and p-Akt antibody (#9272 and #9271), anti-
ERK1/2 and p-ERK1/2 antibody (#9102 and #9101), anti-GSK-3α/β and 
p-GSK-3β antibody (#5676 and #9323) and anti-Bax antibody (#2772) 
were purchased from Cell Signaling Technology (Danvers, MA). Serum 
alanine transaminase and amylase levels were measured by Animal Clinical 
Laboratory Core Facility at UNC-Chapel Hill.
Treadmill. To test whole-body endurance, hamsters were placed on a 
motorized treadmill set at a rate of 15 m/minute at a 15° downward slope. 
Termination of the test occurred when the hamsters remained on the shock 
grid for >10 seconds without attempting to reenter the treadmill.
Membrane integrity testing. For the in vitro membrane repair assay, 
isolated single myofibers from flexor digitorum brevis muscle were 
measured for FM1-43 dye leakage as described before.12 Hamsters were 
euthanized by CO2 inhalation, followed by cervical dislocation. The flexor 
digitorum brevis muscles were surgically excised and placed in a Tyrode 
solution (140 mmol/l NaCl, 5 mmol/l KCl, 2.5 mmol/l CaCl2, 2 mmol/l 
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MgCI2, 10 mmol/l HEPES, pH 7.2). Type I collagenase (2 mg/ml) was used 
to digest the flexor digitorum brevis muscle samples at 37 °C for 2 hours. 
The fibers were plated onto ΔTC3 glass-bottomed dishes in Tyrode solu-
tion containing either 2 mmol/l Ca2+ or 0 mmol/l Ca2+ (plus 0.5 mmol/l 
EGTA) and 2.5 μmol/l FM1-43 dye (Molecular Probes Eugene, OR). To 
induce damage to the muscle fibers, a 5 × 5 pixel area of the plasma mem-
brane was irradiated by UV laser at maximum power (Enterprise, 80 mW, 
351/364 nm) for 5 seconds using a Zeiss-LSM 510 confocal microscope 
equipped with a ×63 water immersion lens (N.A. 1.3). Images were cap-
tured at 5-second intervals. For each image, the mean fluorescence inten-
sity was measured using Zeiss-LSM 510 imaging software. The fluorescence 
intensity was calculated in an area of about 200 μm2 directly adjacent to the 
injury site. Data is presented as a ratio of fluorescence intensity change 
relative to the value before injury (ΔF/F0).
For the in vivo tests of sarcolemma integrity, Evans blue (10 mg/ml in 
phosphate-buffered saline) was intravenously injected into hamsters at a 
dose of 0.1 mg/g body weight. The animals were then sacrificed 12 hours 
later, and cryosections of muscle tissue were analyzed. Leaky myocytes filled 
with Evans blue and showed strong red fluorescence. Blood (0.1 ml) was 
also collected from the saphenous vein for evaluation of serum CK enzyme 
activity, which was assayed using the CK Reagent/UV-Kinetic Method 
(TECO Diagnostics Anaheim, CA) according to manufacturer instructions.
Echocardiography analysis. The noninvasive echocardiography method 
was used to collect heart functional data.3 Echocardiographic studies in 
hamsters were performed at 4.5 and 7.5 months of age in the neonatal treat-
ment group and at 4.5 months of age in the adult treatment group (AAV 
injection at 2 months of age). Hamsters were anesthetized with intraperi-
toneal injection of 2.5% Avertin (150 μl/10 g body weight), secured in a 
shallow left lateral decubitus position over a warming pad, and shaved over 
the chest. A 13.0-MHz transducer was applied to the left hemithorax. Two-
dimensional-targeted M-mode imaging was obtained from the short axis 
immediately below the level of the mitral valve. M-mode measurements 
of LVID;d and LVID;s were made from recorded images by using the 
leading-edge convention of the American Society of Echocardiography. 
Left ventricular percentage fractional shortening (%) was calculated as: 
left ventricular percentage fractional shortening (%) = [(LVID;d-LVID;s)/
LVID;d]/100.
Statistical analysis. Statistic analysis was performed with the one-way 
ANOVA with Bonferroni post-test. The P value was two-tailed and consid-




-dependent MG53-mediated repair patch formation 
in TO-2 muscle fibers.
Figure S2. Amelioration of fibrosis as evaluated by decreasing tis-
sue hydroxyproline content in AAV-MG53-treated muscle and heart 
of TO-2.
Figure S3. miRNA-mediated transgene silencing reduced liver toxic-
ity caused by MG53 overexpression.
Figure S4. Activation of prosurvival kinases in MG53-treated TO-2 
heart.
Figure S5. Immunoblots of proapoptotic factor Bax in hamster 
heart.
Video S1. Representative membrane repair of single myofiber 
 isolated from wild-type F1B.
Video S2. Representative membrane repair of single myofiber 
 isolated from TO-2 hamster.
Video S3. Representative membrane repair of single myofiber 
 isolated from AAV-MG53 treated TO-2 hamster.
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